Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
06/05/2025 22:41
Prelude Therapeutics Inc PRLD.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter ended March 31, identical to the same quarter last year. The mean expectation of three analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -47 cents to -46 cents per share. Reported revenue was zero; analysts expected zero. Prelude Therapeutics Inc's reported EPS for the quarter was a loss of 42 cents. The company reported a quarterly loss of $32.09 million. Prelude Therapeutics Inc shares had risen by 7.0% this quarter and lost 35.6% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 5.6% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold" Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.50 This summary was machine generated from LSEG data May 6 at 09:41 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.47 | -0.42 | Beat |
| Dec. 31 2024 | -0.46 | -0.38 | Beat |
| Sep. 30 2024 | -0.47 | -0.43 | Beat |
| Jun. 30 2024 | -0.43 | -0.46 | Missed |
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview